Open Access

Long noncoding RNA EZR‑AS1 promotes tumor growth and metastasis by modulating Wnt/β‑catenin pathway in breast cancer

  • Authors:
    • Yu Bai
    • Xian Zhou
    • Luo Huang
    • Yue Wan
    • Xiaoyu Li
    • Ying Wang
  • View Affiliations

  • Published online on: July 18, 2018     https://doi.org/10.3892/etm.2018.6461
  • Pages: 2235-2242
  • Copyright: © Bai et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Accumulating evidence has demonstrated that long noncoding RNAs (lncRNAs) serve important roles in tumor development and progression. However, whether lncRNA EZR‑AS1 is associated with breast cancer (BC) progression remains unclear. In the present study, reverse transcription‑quantitative polymerase chain reaction analysis demonstrated that the expression of EZR‑AS1 was significantly upregulated in BC tissues and cell lines. Furthermore, Kaplan‑Meier curve analysis revealed that increased EZR‑AS1 expression in patients with BC contributes to poor prognosis. Cell counting kit‑8 and fluorescence‑activated cell sorting experiments indicated that EZR‑AS1 knockdown significantly suppressed the proliferation and cell cycle progression of breast cancer cells, while reducing cellular apoptosis. Furthermore, Transwell assays suggested that EZR‑AS1 knockdown reduced the migration and invasion ability of BC cells compared with control cells. In the present study, it was observed that EZR‑AS1 interacts with β‑catenin to prevent degradation. EZR‑AS1 knockdown resulted in β‑catenin downregulation and inactivation of the Wnt/β‑catenin pathway. Rescue assays revealed that β‑catenin overexpression reversed the effects of EZR‑AS1 knockdown on BC cell proliferation, apoptosis, migration and invasion. In conclusion, the results of the present study demonstrate that EZR‑AS1 serves as an oncogene in BC via activating the Wnt/β‑catenin pathway. This suggests that EZR‑AS1 may be a therapeutic target for BC treatment.
View Figures
View References

Related Articles

Journal Cover

September-2018
Volume 16 Issue 3

Print ISSN: 1792-0981
Online ISSN:1792-1015

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Bai Y, Zhou X, Huang L, Wan Y, Li X and Wang Y: Long noncoding RNA EZR‑AS1 promotes tumor growth and metastasis by modulating Wnt/β‑catenin pathway in breast cancer. Exp Ther Med 16: 2235-2242, 2018
APA
Bai, Y., Zhou, X., Huang, L., Wan, Y., Li, X., & Wang, Y. (2018). Long noncoding RNA EZR‑AS1 promotes tumor growth and metastasis by modulating Wnt/β‑catenin pathway in breast cancer. Experimental and Therapeutic Medicine, 16, 2235-2242. https://doi.org/10.3892/etm.2018.6461
MLA
Bai, Y., Zhou, X., Huang, L., Wan, Y., Li, X., Wang, Y."Long noncoding RNA EZR‑AS1 promotes tumor growth and metastasis by modulating Wnt/β‑catenin pathway in breast cancer". Experimental and Therapeutic Medicine 16.3 (2018): 2235-2242.
Chicago
Bai, Y., Zhou, X., Huang, L., Wan, Y., Li, X., Wang, Y."Long noncoding RNA EZR‑AS1 promotes tumor growth and metastasis by modulating Wnt/β‑catenin pathway in breast cancer". Experimental and Therapeutic Medicine 16, no. 3 (2018): 2235-2242. https://doi.org/10.3892/etm.2018.6461